Compare SentinelOne Inc. Class A Common Stock (S) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SentinelOne Inc. Class A Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? SentinelOne Inc. Class A Common Stock trades at $22.64 (market cap $8.36B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: SentinelOne Inc. Class A Common Stock and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and SentinelOne Inc. Class A Common Stock is more actively traded (27,558,313 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold SentinelOne Inc. Class A Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| S | SYRE | |
|---|---|---|
Market Cap | $8.36B | $7.52B |
Volume | 27,558,313 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $26.27 | $108.92 |
52-Week Low | $11.94 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.74B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SentinelOne (S) trades at $24.01, down 6.43% amid news of a $1.25 billion convertible notes offering. The stock shows bullish technical signals with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains robust revenue growth (21% YoY) and high gross margins (72.54%) but continues to report significant net losses (-$288M in 2025). Recent analyst recognition as a leader in endpoint security and expanding cloud capabilities provide positive business momentum.
Investment outlook balances strong growth potential against persistent profitability challenges. The convertible notes offering signals aggressive expansion but increases financial leverage. With 65% analyst buy ratings and a $23.42 consensus target, Wall Street remains optimistic about long-term cybersecurity demand, though investors face execution risk and competitive pressures in a capital-intensive growth phase.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SentinelOne Inc. Class A Common Stock
SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
